{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Cancer+%28Locally+Advanced+or+Metastatic%29&page=4", "query": { "condition": "Colorectal Cancer (Locally Advanced or Metastatic)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 109, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Cancer+%28Locally+Advanced+or+Metastatic%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Cancer+%28Locally+Advanced+or+Metastatic%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T19:55:49.542Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00648102", "title": "Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Bladder Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CDX-1307", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2006-01", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2010-07-26", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 3, "location_summary": "Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00648102" }, { "nct_id": "NCT06364696", "title": "A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ASP4396", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-04-16", "completion_date": "2026-06-17", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 7, "location_summary": "Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more", "locations": [ { "city": "Westwood", "state": "Kansas" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06364696" }, { "nct_id": "NCT00551421", "title": "Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "pertuzumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "fluorescence in situ hybridization", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "mutation analysis", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2007-10", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2015-03-31", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551421" }, { "nct_id": "NCT06934538", "title": "First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Metastatic Colorectal Cancer", "Unresectable Locally Advanced Colorectal Cancer" ], "interventions": [ { "name": "STC-1010 + IS regimen + SOC therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Brenus Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2025-06-17", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06934538" }, { "nct_id": "NCT00080834", "title": "DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "DJ-927", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2004-02", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 2, "location_summary": "Albuquerque, New Mexico • Houston, Texas", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080834" }, { "nct_id": "NCT05719558", "title": "A Study of ASP1002 in Adults for Treatment of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1002", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trifluridine-Tipiracil", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2023-03-13", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 15, "location_summary": "New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Plainville", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05719558" }, { "nct_id": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Cancer", "Solid Tumor", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer" ], "interventions": [ { "name": "ACE1702", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acepodia Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-06-24", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 2, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04319757" }, { "nct_id": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Triple Negative Breast Cancer", "HR+/HER2- Breast Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" }, { "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2016-12-19", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983045" }, { "nct_id": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Cancer", "Melanoma", "Non-Small-Cell Lung Cancer", "Hepatocellular Cancer", "Bladder Cancer", "Sarcoma", "Head and Neck Cancer", "Colorectal Cancer", "Ovarian Cancer", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "PF-07263689", "type": "BIOLOGICAL" }, { "name": "Sasanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-10-20", "completion_date": "2022-10-14", "has_results": true, "last_update_posted_date": "2024-04-12", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061537" }, { "nct_id": "NCT04511039", "title": "Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A", "Locally Advanced Colorectal Carcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" }, { "name": "Talazoparib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-06-08", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-09T19:55:49.542Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511039" } ] }